Claims for Patent: 9,493,743

Summary for Patent: 9,493,743

Title:	Production of a human beta cell line from an early post natal pancreas
Abstract:	The present invention relates to a method for preparing commercial scale quantities of human functional beta cells and to the establishment of cell lines from non-foetal pancreatic tissues. It also relates to a method of diagnosis using beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing to generate human Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation. They have a gene expression profile that resembles to adult beta cells. In addition, the human beta cell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities.
Inventor(s):	Czernichow; Paul (Paris, FR), Ravassard; Philippe (Paris, FR), Scharfmann; Raphael (Paris, FR)
Assignee:	UNIVERCELL BIOSOLUTIONS (Toulouse, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR)
Application Number:	14/352,519
Patent Claims:	1. A method of preparing human pancreatic beta cells or human beta cell tumors, wherein said human pancreatic beta cells or human beta cell tumors express insulin and PDX-1, said method comprising the steps of: a) dissociating neonatal human pancreatic tissue with collagenase in order to obtain neonatal human pancreas cells, b) transducing and co-transducing the neonatal human pancreas cells obtained in step a) with i) a lentiviral vector expressing only SV40 LargeT antigen under the control of the insulin promoter or ii) with a lentiviral vector expressing only SV40 LargeT antigen under the control of the insulin promoter and a lentiviral vector expressing only hTERT under the control of the insulin promoter, or iii) a lentiviral vector expressing both SV40 LargeT antigen and hTERT but no other oncogene, c) introducing the transduced neonatal pancreas obtained in b) into the kidney capsule of a first severe combined immunodeficiency (scid) mouse, d) allowing the transduced pancreas cells to develop insulinoma-like structures, wherein the neonatal human pancreas cells in insulinoma-like structures have differentiated in insulin-producing pancreatic beta cells; e) micro-dissecting the insulinoma-like structures obtained in step d), dissociating the cells thereof, f) sub-transplanting the cells obtained in step e) into the kidney capsule of a second scid mouse, g) allowing the sub-transplanted cells in step f) to develop and regenerate insulinoma-like structures, wherein said newly developed insulinoma-like structures are enriched in insulin producing pancreatic beta cells; h) micro-dissecting the insulinoma-like structures obtained in step g), and dissociating and collecting the cells thereof, i) optionally, sub-transplantating the cells obtained in step g) into the kidney capsule of a third scid mouse, to further enrich and amplify insulin-producing pancreatic beta cells; and j) optionally repeating steps f), g) and h) until an appropriate amount of insulin-producing pancreatic beta cells is obtained, wherein the insulin-producing pancreatic beta cells allow insulinoma formation and restoration of normoglycemia in diabetic SCID mice. 2. The method of claim 1, wherein the construction of the lentiviral vectors allows reversible or conditional immortalization. 3. The method of claim 1, wherein the lentiviral vectors comprise at least one Lox P site and the SV40 LargeT and/or hTERT genes are removed by the action of the Cre recombinase. 4. The method of claim 1, wherein the lentiviral vectors comprise at least one FRT site and the SV40 LargeT and/or hTERT genes are removed by the action of FLP recombinase. 5. The method of claim 1, wherein the lentiviral vector expressing SV40 LargeT and the lentiviral vector expressing hTERT further comprise a LoxP or a FLP site, provided that the site specific recombination sites are different in said vectors. 6. The method of claim 1, wherein a negative selection step is performed after the action of the Cre or FLP recombinase to select only the cells in which the immortalization genes SV40 LargeT and/or hTERT have been removed. 7. The method of claim 1, wherein said lentiviral vectors include at least one negative selection marker gene. 8. The method of claim 7, wherein the negative marker gene is selected from the group consisting of the HSV-TK gene, the hypoxanthine phosphoribosyl transferase (HPRT) gene, the guanine-phosphoribosyl-transferase (Gpt) gene, and the cytosine deaminase gene. 9. The method of claim 1, further comprising transducing the cells of step e) with a lentiviral vector expressing an antibiotic resistance gene under control of the insulin promoter. 10. The method of claim 9, wherein the antibiotic resistance gene is a neomycin resistance gene. 11. The method of claim 1, further comprising collecting the human pancreatic beta cells obtained at step j) to form an homogenous cell population and optionally culturing said population in vitro to establish a human functional beta cell line. 12. The method of claim 1, wherein said collagenase is collagenase XI. 13. The method of claim 1, further comprising one or more de-immortalizing step(s) including removing the SV40 LargeT, the hTERT and/or the antibiotic resistance transgenes.

Details for Patent 9,493,743

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29